Want to see SER full AI Analyst Report?
Serina Therapeutics (SER) AI Stock Analysis
Serina Therapeutics
(NYSE MKT:SER)
Overall score is weighed down primarily by weak financial performance (no TTM revenue, sizable losses, and high ongoing cash burn), with technicals also negative as the stock trades below key moving averages and shows weak momentum. Corporate actions provide some support by improving capital-structure clarity and financing flexibility, but potential dilution and loss-making valuation characteristics keep the score in the low range.
Serina Therapeutics (SER) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $29.10M
- Dividend Yield
- ―
- Average Volume (3M)
- 70.20K
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- 0.22
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 16
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Serina Therapeutics Business Overview & Revenue Model
Company Description
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company...
Serina Therapeutics Financial Statement Overview
Summary
Financials reflect a pre-commercial, high-cash-burn profile: TTM shows no revenue with large losses (EBIT -$25.7M; net loss -$21.2M) and significant negative free cash flow (-$21.2M). Balance sheet leverage is low (debt ~$0.12M vs. equity ~$18.7M), but historical equity volatility and ongoing losses elevate dilution/financing risk.
Income Statement
18Very NegativeBalance Sheet
54NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 56.00K | 3.15M | 500.00K | 3.46M |
| Gross Profit | -7.07M | 0 | -138.00K | 3.06M | 500.00K | -333.84K |
| EBITDA | -22.13M | -18.91M | -10.49M | 5.92M | -2.60M | -1.23M |
| Net Income | -21.18M | -19.18M | -11.14M | 5.27M | -2.68M | -1.26M |
Balance Sheet | ||||||
| Total Assets | 25.81M | 6.95M | 6.72M | 8.97M | 3.24M | 3.15M |
| Cash, Cash Equivalents and Short-Term Investments | 23.02M | 3.06M | 3.67M | 7.62M | 645.00K | 584.00K |
| Total Debt | 3.21M | 196.00K | 268.00K | 3.44M | 18.12M | 13.20M |
| Total Liabilities | 7.08M | 6.99M | 6.22M | 41.26M | 20.56M | 15.03M |
| Stockholders Equity | 18.73M | -37.00K | 641.00K | -32.29M | -17.21M | -11.83M |
Cash Flow | ||||||
| Free Cash Flow | -21.17M | -17.95M | -17.16M | -2.98M | -2.09M | -2.36M |
| Operating Cash Flow | -21.14M | -17.95M | -17.14M | -2.48M | -2.08M | -2.25M |
| Investing Cash Flow | -66.00K | -59.00K | -22.00K | -504.00K | 980.94K | 823.32K |
| Financing Cash Flow | 38.18M | 17.41M | 13.21M | 10.07M | 1.31M | 1.08M |
Serina Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Neutral. The current price of 1.97 is above the 20-day moving average (MA) of 1.82, below the 50-day MA of 2.15, and below the 200-day MA of 2.09, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 52.33 is Neutral, neither overbought nor oversold. The STOCH value of 67.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SER.
Serina Therapeutics Risk Analysis
Serina Therapeutics disclosed 74 risk factors in its most recent earnings report. Serina Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSerina Therapeutics Peers Comparison
Overall Rating
- SER44Neutral
CELU44Neutral
SKYE43Neutral
OTLK42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SER | 44Neutral | $49.28M | -1.03 | -222.42% | ― | ― | ― |
| CELU | 44Neutral | $25.96M | -0.45 | 142.25% | ― | -58.14% | 47.25% |
| SKYE | 43Neutral | $5.67M | -0.13 | -329.08% | ― | ― | -19.07% |
| OTLK | 42Neutral | $113.96M | -0.42 | 222.01% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SER | Serina Therapeutics, Inc. | 1.94 | -2.74 | -58.55% | |
| OTLK | Outlook Therapeutics | 0.47 | -0.83 | -64.00% | |
| SKYE | Skye Bioscience, Inc. | 1.28 | -10.72 | -89.33% | |
| CELU | Celularity Inc. | 0.80 | -0.92 | -53.49% | |
| JUNS | Jupiter Neurosciences, Inc. | 2.05 | -96.95 | -97.93% |
Serina Therapeutics Corporate Events
Serina Therapeutics Streamlines Capital Structure After Preferred Elimination
PositiveOn October 5, 2026, Serina Therapeutics, Inc. filed a Certificate of Elimination in Delaware to remove all provisions related to its Series A Convertible Preferred Stock from its amended and restated certificate of incorporation. This action follows...
Serina Therapeutics Establishes Flexible Equity Financing Agreement
PositiveOn August 21, 2026, Serina Therapeutics entered into a Common Stock Purchase Agreement and related Registration Rights Agreement with Roth Principal Investments, giving the company the discretionary right to sell up to $25 million of newly issued com...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 10, 2026